Skip to main content

Cosentyx Side Effects

Generic name: secukinumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on May 23, 2022.

Note: This document contains side effect information about secukinumab. Some dosage forms listed on this page may not apply to the brand name Cosentyx.

Applies to secukinumab: solution.

Serious side effects of Cosentyx

Along with its needed effects, secukinumab (the active ingredient contained in Cosentyx) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking secukinumab:

More common

Less common

Rare

Incidence not known

Other side effects of Cosentyx

Some side effects of secukinumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to secukinumab: intravenous solution, subcutaneous powder for injection, subcutaneous solution.

Dermatologic

Uncommon (0.1% to 1%): Tinea pedis, urticaria[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, oral herpes

Uncommon (0.1% to 1%): Oral candidiasis

Frequency not reported: Exacerbation of inflammatory bowel disease (IBD)[Ref]

Hypersensitivity

Rare (less than 0.1%): Anaphylaxis[Ref]

Immunologic

Uncommon (0.1% to 1%): Immunogenicity

Frequency not reported: Candida infections, herpes viral infections, staphylococcal skin infections, infections requiring treatment (increased as serum concentration of this drug is increased), neutropenia[Ref]

Respiratory

Very common (10% or more): Nasopharyngitis (11%)

Common (1% to 10%): Upper respiratory tract infection, rhinitis, pharyngitis, rhinorrhea[Ref]

Hematologic

Uncommon (0.1% to 1%): Neutropenia[Ref]

Ocular

Uncommon (0.1% to 1%): Conjunctivitis[Ref]

Other

Uncommon (0.1% to 1%): Otitis externa[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.